Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Ex-BoE man highlights alleged ‘insider trading bonanza’ at Astra

Ex-BoE man highlights alleged ‘insider trading bonanza’ at Astra

A former senior adviser to the Bank of England has highlighted unusual trading patterns in AstraZeneca before it publicly disclosed a takeover approach from Pfizer.

AstraZeneca revealed on Monday that Ian Read, chairman and chief executive of Pfizer, had first contacted it on 25 November 2013 to ‘discuss a combination’.

AstraZeneca subsequently staged ‘an exploratory meeting’ with Pfizer on 5 January 2014 in New York. Neither event was announced to markets.

In the six months until November 2013, AstraZeneca’s share price had lagged the wider FTSE 100, losing 1.5% while the index gained 4.7%.

Since November, AstraZeneca’s stock has surged 14.3% while the FTSE 100 has dropped 1.6%.

The divergence between the two was most marked in January when AstraZeneca rose by 8% and the index fell by 3.5%.

January also brought a spike in the trading of AstraZeneca shares. Between May 2013 and December 2013, trading volumes were consistently around £1.5 billion per month. This leapt to £2.5 billion in January, and has remained above £2 billion since then.

Since 31 October 2013, AstraZeneca has released three sets of financial results. Each of these featured double-digit percentage declines in both the company’s profits and earnings per share.

In a blog today entitled ‘AstraZeneca: Insider Trading Bonanza???’ for the Cass Business School, where he is a lecturer, Peter Hahn supposed that regulators would take a keen interest in these patterns, although there is not concrete evidence of insider dealing.

‘The lack of an AstraZeneca board announcement will certainly be questioned, but it looks like a dead certainty that many a regulator and lawyer will be very busy,’ commented Hahn, who from 2009 until March 2014 was a senior adviser to the Bank of England focused on the Prudential Regulation Authority.

A spokesperson for AstraZeneca declined to comment.

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Mark Barnett - part 2: why I'm not buying Lloyds

Mark Barnett - part 2: why I'm not buying Lloyds

In the second part of our exclusive video interview, Barnett explains why he has no intention of buying Lloyds, and where he sees the greatest income opportunities.

Play Wealth managers reveal the best investment ideas of the year

Wealth managers reveal the best investment ideas of the year

From robotics to impact investing, wealth managers share the best ideas they have heard this year.

Play Baillie Gifford's Earnshaw on Xi Jinping's 'new era'

Baillie Gifford's Earnshaw on Xi Jinping's 'new era'

Sophie Earnshaw talks through what Xi Jinping's 'new era' means for investors. and why Chinese tech offers some of best growth stocks in the world.

Read More
Your Business: Cover Star Club

Profile: JM Finn on why the future is with financial planners

Profile: JM Finn on why the future is with financial planners

There is a lot of work on pension consolidation and Sipps have been a big driver there, says JM Finn chief executive

Wealth Manager on Twitter